Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Biomarker dynamics affecting neoadjuvant therapy response and outcome of HER2-positive breast cancer subtype ; volume:13 ; number:1 ; day:8 ; month:8 ; year:2023 ; pages:1-14 ; date:12.2023
Scientific reports ; 13, Heft 1 (8.8.2023), 1-14, 12.2023
- Urheber
-
Orrù, Sandra
Pascariello, Emanuele
Pes, Barbara
Rallo, Vincenzo
Barbara, Raffaele
Muntoni, Marta
Notari, Francesca
Fancello, Gianfranco
Mocci, Cristina
Muroni, Maria Rosaria
Cossu-Rocca, Paolo
Angius, Andrea
Miglio, Maria Rosaria De
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-023-40071-2
- URN
-
urn:nbn:de:101:1-2024020613103238327436
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Orrù, Sandra
- Pascariello, Emanuele
- Pes, Barbara
- Rallo, Vincenzo
- Barbara, Raffaele
- Muntoni, Marta
- Notari, Francesca
- Fancello, Gianfranco
- Mocci, Cristina
- Muroni, Maria Rosaria
- Cossu-Rocca, Paolo
- Angius, Andrea
- Miglio, Maria Rosaria De
- SpringerLink (Online service)
Ähnliche Objekte (12)
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer
HER2-Positive Metaplastic Breast Cancer with Resistance to Neoadjuvant Chemotherapy: Case Report
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer
Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy
Is the (Neo) adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering? : Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Adjuvant breast cancer: (neo)adjuvant therapy for HER2-positive breast cancer : The best of ASCO 2019
Association between pathologic complete response and biochemical indicators after neoadjuvant therapy for HER2-positive breast cancer
Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer